221 related articles for article (PubMed ID: 22315053)
1. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
[TBL] [Abstract][Full Text] [Related]
2. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
3. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
[TBL] [Abstract][Full Text] [Related]
5. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
[TBL] [Abstract][Full Text] [Related]
6. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
7. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
[TBL] [Abstract][Full Text] [Related]
8. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
[TBL] [Abstract][Full Text] [Related]
9. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
Giampieri R; Puzzoni M; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Germano D; Zagonel V; Codecà C; Libertini M; Labianca R; Cascinu S; ; Scartozzi M
Br J Cancer; 2017 Oct; 117(8):1099-1104. PubMed ID: 28926529
[TBL] [Abstract][Full Text] [Related]
10. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
11. Use of bevacizumab in the treatment of metastatic colorectal cancer.
Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
[TBL] [Abstract][Full Text] [Related]
12. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
Moscetti L; Nelli F; Fabbri MA; Sperduti I; Alesini D; Cortesi E; Gemma D; Gamucci T; Grande R; Pavese I; Franco D; Ruggeri EM
Invest New Drugs; 2013 Aug; 31(4):1035-43. PubMed ID: 23417697
[TBL] [Abstract][Full Text] [Related]
13. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Scartozzi M; Galizia E; Chiorrini S; Giampieri R; Berardi R; Pierantoni C; Cascinu S
Ann Oncol; 2009 Feb; 20(2):227-30. PubMed ID: 18842611
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
[TBL] [Abstract][Full Text] [Related]
15. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
[TBL] [Abstract][Full Text] [Related]
16. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results.
Hofheinz R; Petersen V; Kindler M; Schulze M; Seraphin J; Hoeffkes HG; Valdix AR; Schroeder J; Herrenberger J; Stein A; Hinke A; Arnold D
BMC Cancer; 2014 Oct; 14():761. PubMed ID: 25311943
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
19. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
20. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
